trial
as of 2026-07-01Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
NCTId NCT02943213
at a glance
Phase 1 · Completed
Enrollment 20 (actual)
Sponsored by Cycle Pharmaceuticals Ltd.
Primary completion 2016-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
None
Start
2016-11
Primary completion
2016-12
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Adjunct in the Treatment of TetanusAcute Intermittent PorphyriaRelief of Intractable HiccupsAnti-PsychoticPorphyria, Acute IntermittentManagement of Manifestations of Psychotic DisordersTreatment of SchizophreniaRelief of Restlessness and Apprehension Before SurgeryControl Manifestations of the Manic Type of Mani-depressive IllnessControl Nausea and VomitingVomiting
Sponsors
Cycle Pharmaceuticals Ltd.Lead Sponsor
ParexelCollaborator
Investigators
1
Dr. Yolandi Swart, FCPHM(SA)Principal Investigator
Sites
1 total
Bloemfontein, South Africa
Facts & assertions
4 sourced
Enrollment
20
Phase
PHASE1
Primary Completion Date
2016-12
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
indication
indication
indication
investigator